Coombs test

Thermo Fisher Scientific Introduces Array-based Solution for Extended Blood Type Research to Support Future Advancements Toward Safer Transfusions

Retrieved on: 
水曜日, 5月 15, 2024
Managed Care, Software, Research, Pharmaceutical, Technology, Medical Devices, Genetics, Surgery, Clinical Trials, Science, Biotechnology, Health, Other Science, HLA, Partnership, Anti-transglutaminase antibodies, Patient, Genomics, Antigen, DNA, Coombs test, University, Transplant, Risk, RH, Vision, AB, Safety, HPA, Gene, Workflow, Blood transfusion, Quality control, Thermo Fisher Scientific, Platelet transfusion, Experimental Hematology, BGC, Applied Biosystems, Antibody, Axiom, Medical device

Blood typing is a critical medical service used to match blood and tissue types ahead of transfusions and transplants.

Key Points: 
  • Blood typing is a critical medical service used to match blood and tissue types ahead of transfusions and transplants.
  • Therefore, research is critical to bring extended blood typing into strategies to mitigate potential risks of hemolytic transfusion reactions in the future.
  • “The Axiom BloodGenomiX Array and Software provide a cost-effective, high-throughput solution for extended blood typing research,” said Kevin Lowitz, vice president and general manager, microarray solutions at Thermo Fisher Scientific.
  • “In the future, having access to a scalable, array-based blood typing solution may help blood services effectively screen extended blood types for more precise blood matching.”
    For more information, please visit thermofisher.com/extendedbloodtyping and read the white paper, “ Genotyping for extended and rare blood types .”
    *For research use only.

Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs

Retrieved on: 
火曜日, 5月 7, 2024
Inflammation, NEA, Science, CD19, Patient, Pivotal, Coombs test, B cell, Wellington Management Company, Health, Norwest Venture Partners, I&I, Sclerosis, Multiple sclerosis, Pharmaceutical industry

WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology-directed therapies, today announced the closing of an upsized $200 million Series C preferred stock financing. The financing round was led by SR One along with NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences and Longitude Capital. Additional new investors, the Federated Hermes Kaufmann Funds, and Arrowmark Partners, along with existing investors, Fairmount, Wellington Management, Rock Springs Capital, Pivotal bioVenture Partners, Vivo Capital, Quan Venture Fund, and Superstring Capital participated in the financing. In conjunction with the financing, Jake Nunn, venture partner at SR One, and Tim Xiao, Partner at Delos Capital, joined Zenas’ Board of Directors.

Key Points: 
  • The financing round was led by SR One along with NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences and Longitude Capital.
  • In conjunction with the financing, Jake Nunn, venture partner at SR One, and Tim Xiao, Partner at Delos Capital, joined Zenas’ Board of Directors.
  • “Their commitment to Zenas is a testament to our vision to be a global leader in bringing innovative immunology-based therapies to patients around the world.
  • “At SR One, we invest in companies like Zenas whose science has the potential to rewrite the medical textbooks and meaningfully transform patient care.

WellSky® Joins Collaborative Effort to Improve Transfusion Safety Through National Alloantibody Exchange

Retrieved on: 
火曜日, 2月 7, 2023
Cardiology, Software, Practice Management, Data Analytics, Health, Hospitals, Professional Services, Technology, Blood, Patient safety, LifeSouth Community Blood Centers, Hospital, Coombs test, Blood transfusion, Food, Antigen, Kansas City metropolitan area, Criticism of the Food and Drug Administration, Medical device, Blood product

WellSky , a leading health and community care technology company, today announced a collaborative effort with the Alloantibody Exchange , a non-profit dedicated to improving blood transfusion safety and building a national transfusion antibody registry easily accessible to both hospitals and blood banks.

Key Points: 
  • WellSky , a leading health and community care technology company, today announced a collaborative effort with the Alloantibody Exchange , a non-profit dedicated to improving blood transfusion safety and building a national transfusion antibody registry easily accessible to both hospitals and blood banks.
  • The Alloantibody Exchange works with technology partners like WellSky to facilitate access to red blood cell antibody information across hospital transfusion services.
  • “We started the Alloantibody Exchange because transfusion recipients were receiving incompatible blood, and it seemed largely preventable,” said Dr. George Hauser, president and founder of the Alloantibody Exchange.
  • The Alloantibody Exchange will provide WellSky clients with secure and near real-time access to this important data.”
    WellSky is joining 45 leading hospitals in recognition of the important blood transfusion safety benefits of the Alloantibody Exchange.

Menarini Silicon Biosystems Begins Distribution of Rapid COVID-19 Antibody Test in North America

Retrieved on: 
水曜日, 6月 10, 2020
Medical specialties, Branches of biology, Medicine, Glycoproteins, Antibodies, Immunology, Immunoglobulin M, Blood tests, Immunologic tests, Immunoglobulin G, Typhidot, Coombs test

The test is also available in Europe through A. Menarini Diagnostics, the European diagnostics division of The Menarini Group.

Key Points: 
  • The test is also available in Europe through A. Menarini Diagnostics, the European diagnostics division of The Menarini Group.
  • Healgen's COVID-19 IgG/IgM Rapid Test Cassette detects two types of antibodies, immunoglobulin G (IgG) and immunoglobulin M (IgM), in just 10 minutes.
  • To use the test, healthcare workers place a small sample of serum or plasma or one drop of blood on a test cassette.
  • Antibody tests that have EUA are preferred for public health and clinical use since their test performance data have been reviewed by FDA.

First USA At-Home Collection Kit Detects Exposure And Immunity To COVID-19

Retrieved on: 
火曜日, 3月 31, 2020
Medical specialties, Medicine, Branches of biology, Immunology, Glycoproteins, Antibodies, Immunoglobulin G, Immunity, Transfusion medicine, Blood tests, Coombs test, Typhidot

The test, which examines two antibodies IgM and IgG has been scientifically proven to accurately and reliably detect COVID-19 antibodies, when tested at least seven days after exposure.

Key Points: 
  • The test, which examines two antibodies IgM and IgG has been scientifically proven to accurately and reliably detect COVID-19 antibodies, when tested at least seven days after exposure.
  • While all tests are ordered and performed by Dr. Vojdani in office, this is not an at-home COVID-19 test, rather it's to test exposure and immunity to the virus.
  • The simple finger prick kit provides confidential results through an online portal within 48 hours after the blood sample has been received.
  • The COVID-19 Exposure & Immunity Test can be ordered online through RootMD .